Lugowska, I.
The Maria Sklodowska-Curie National Research Institute of Oncology
3 papers on CoChatORCID 0000-0001-9511-178X
Most cited papers
- Verified
Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology
Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments
Cited by 617
- Verified
FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
Siefker-Radtke, A. O., Currie, G., Abella, E., Vaena, D. A., Rezazadeh Kalebasty, A., Curigliano, G., Tupikowski, K., Andric, Z. G., Lugowska, I., & Kelly, W. K. (2019) · Journal of Clinical Oncology
Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor Research
Cited by 64
- Verified
620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Shenderov, E., Mallesara, G. H. G., Wysocki, P. J., Xu, W., Ramlau, R., Weickhardt, A. J., Zolnierek, J., Spira, A., Joshua, A. M., Powderly, J., et al. (2021) · Annals of Oncology
Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and Inhibitors
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free